A recent study, published in the European Review for Medical and Pharmacological Sciences last month, identified tyrosine kinase receptor (TEK) as a potential novel prognostic biomarker for clear cell renal cell carcinoma (ccRCC).
TEK is a protein receptor found on the surface of tumour cells. It plays an important role in the growth of new blood vessels (angiogenesis). This study showed that a suppressed response of the TEK receptor was associated with a poor prognosis for patients with ccRCC.
The researchers concluded that the results from this study suggest that TEK is a potential biomarker for ccRCC, although further clinical research is needed to verify these results.